pharmachologic effect
DNA recombinant analogue of human insulin. It differs from the latter in the reverse sequence of amino acids at positions 28 and 29 of the insulin B chain.
The main action of the drug is the regulation of glucose metabolism. In addition, it has an anabolic effect. In muscle tissue, there is an increase in the content of glycogen, fatty acids, glycerol, an increase in protein synthesis and an increase in the consumption of amino acids, but at the same time there is a decrease in glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and the release of amino acids.
In patients with type 1 and 2 diabetes mellitus, insulin lispro significantly reduces postprandial hyperglycemia compared to soluble human insulin. For patients receiving short-acting and basal insulin, it is necessary to adjust the dose of both insulins in order to achieve optimal blood glucose levels throughout the day.
As with all insulin preparations, the duration of action of insulin lispro may vary in different patients or at different times in the same patient and depends on the dose, injection site, blood supply, body temperature and physical activity.
The pharmacodynamic profile of insulin lispro in children and adolescents is similar to that observed in adults.
In patients with type 2 diabetes mellitus receiving the highest doses of sulfonylurea derivatives, the addition of insulin lispro leads to a significant decrease in glycated hemoglobin.
Treatment with insulin lispro in patients with type 1 and 2 diabetes mellitus is associated with a reduction in the number of nocturnal hypoglycemia episodes.
The glucodynamic response to isulin lispro does not depend on the functional insufficiency of the kidneys or liver.
Insulin lispro has been shown to be equimolar to human insulin, but its action is more rapid and lasts for a shorter time.
Insulin lispro is characterized by a rapid onset of action (about 15 minutes), because has a high absorption rate, and this allows you to enter it immediately before a meal (0-15 minutes before a meal) in contrast to conventional short-acting insulin (30-45 minutes before a meal). Insulin lispro has a shorter duration of action (2 to 5 hours) than regular human insulin.
Pharmacokinetics
Suction and distribution
After s / c injection, insulin lispro is rapidly absorbed and reaches Cmax in blood plasma after 30-70 minutes. Vd insulin lispro and regular human insulin are identical and are in the range of 0.26-0.36 l / kg.
breeding
With subcutaneous administration, T1 / 2 of insulin lispro is about 1 hour. In patients with renal and hepatic insufficiency, a higher absorption rate of insulin lispro remains compared to conventional human insulin.
Indications for Humalog®
diabetes mellitus in adults and children, requiring insulin therapy to maintain normal glucose levels.Dosing regimen
The doctor determines the dose individually, depending on the needs of the patient. Humalog® can be administered shortly before a meal, if necessary, immediately after a meal.
The temperature of the administered drug should correspond to room temperature.
Humalog® is administered s.c. as an injection or as an extended s.c. infusion using an insulin pump. If necessary (ketoacidosis, acute illness, period between operations or postoperative period), Humalog® can be administered intravenously.
P / c should be injected into the shoulder, thigh, buttocks or abdomen. Injection sites should be alternated so that the same site is used no more than once a month. When s / c administration of the drug Humalog®, care must be taken to avoid getting the drug into the blood vessel. After the injection, do not massage the injection site. The patient must be taught the correct injection technique.
Rules for administering Humalog®
Preparation for the introduction
The solution of Humalog® should be clear and colorless. A cloudy, thickened or slightly colored solution of the drug, or if solid particles are visually detected in it, should not be used.
When installing the cartridge in a pen (pen-injector), attaching a needle and injecting insulin, you must follow the manufacturer’s instructions that are included with each syringe pen.
Introduction
1.Wash your hands.
2. Choose an injection site.
3. Treat the skin at the injection site with an antiseptic.
4. Remove the cap from the needle.
5. Fix the skin by pulling it or pinching a large fold. Insert the needle in accordance with the instructions for using the syringe pen.
6. Press the button.
7. Remove the needle and gently press the injection site for a few seconds. Do not rub the injection site.
8. Using the protective cap of the needle, unscrew the needle and destroy it.
9. Injection sites should be rotated so that the same site is used no more than about 1 time per month.
In / in the introduction of insulin
Intravenous injections of Humalog® should be administered in accordance with normal clinical practice for intravenous injection, for example, by intravenous bolus injection or using an infusion set. This requires frequent monitoring of blood glucose levels.
Systems for infusion with concentrations from 0.1 IU / ml to 1.0 IU / ml of insulin lispro in 0.9% sodium chloride solution or 5% dextrose solution are stable at room temperature for 48 hours.
Subcutaneous insulin infusion with an insulin pump
For Humalog® infusion, Minimed and Disetronic insulin infusion pumps can be used. It is necessary to strictly follow the instructions that came with the pump. The system for infusion is changed every 48 hours. When connecting the system for infusion, observe the rules of asepsis. In the event of a hypoglycemic episode, the infusion is stopped until the episode resolves. If recurring or very low blood glucose levels are noted, this should be reported to the physician and consideration should be given to reducing or stopping the insulin infusion. A malfunctioning pump or clogged infusion set can cause glucose levels to rise rapidly. If you suspect a violation of the supply of insulin, you must follow the instructions and, if necessary, inform the doctor. When using a pump, Humalog should not be mixed with other insulins.
Side effect
Side effect associated with the main action of the drug: hypoglycemia. Severe hypoglycemia can lead to loss of consciousness (hypoglycemic coma) and, in exceptional cases, death.
Allergic reactions: local allergic reactions are possible – redness, swelling or itching at the injection site (usually disappear within a few days or weeks); systemic allergic reactions (occur less often, but are more serious) – generalized itching, urticaria, angioedema, fever, shortness of breath, lowering blood pressure, tachycardia, increased sweating. Severe cases of systemic allergic reactions can be life-threatening.
Local reactions: lipodystrophy at the injection site.
Buy Humalog
Price Humalog
Цена Хумалог
Купить Хумалог
Acheter Humalog
Prix Humalog
Comprar Humalog
Precio Humalog
